RxDoctor Payments Data

Brandy Heaton, APRN

Family · Albuquerque, NMNPI 1346719291

Payments from drug & device makers

$1,517in general payments, 2019–2025

Across 87 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$373
  • Lilly USA, LLC$162
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$161
  • Exact Sciences$105
  • Novo Nordisk$105
  • Otsuka America Pharmaceutical, Inc.$96
  • plus $516 from 14 others

What the payments were for

  • Food & beverage$1,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,517 in reported general payments places this provider in the 85th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$58,526
Medicare patients
179
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide23$45,098
MounjaroTirzepatide25$42,758
OzempicSemaglutide12$19,339
TrulancePlecanatide14$11,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,354
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,878
Levothyroxine Sodium172$1,608
Gabapentin116$1,547
Atorvastatin Calcium111$1,459
Albuterol Sulfate HfaAlbuterol Sulfate68$1,449
Montelukast Sodium38$858
Omeprazole48$794
Celecoxib30$643
Amlodipine Besylate59$625
Rosuvastatin Calcium65$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$162$87,85648 claims
Novo NordiskOzempic$105$19,33912 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$373$11,35414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →